Tyrosine kinase inhibitors - Revision history

Michael: /* Use */

2015-06-05T01:35:16Z

Use

← Older revision		Revision as of 01:35, 5 June 2015
Line 14:		Line 14:
	*[[Lung adenocarcinoma]].		*[[Lung adenocarcinoma]].
	*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal \| last1 = Song \| first1 = Z. \| last2 = Lin \| first2 = B. \| last3 = Shao \| first3 = L. \| last4 = Zhang \| first4 = Y. \| title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. \| journal = J Chin Med Assoc \| volume = 76 \| issue = 9 \| pages = 481-5 \| month = Sep \| year = 2013 \| doi = 10.1016/j.jcma.2013.05.007 \| PMID = 23769878 }}</ref>		*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal \| last1 = Song \| first1 = Z. \| last2 = Lin \| first2 = B. \| last3 = Shao \| first3 = L. \| last4 = Zhang \| first4 = Y. \| title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. \| journal = J Chin Med Assoc \| volume = 76 \| issue = 9 \| pages = 481-5 \| month = Sep \| year = 2013 \| doi = 10.1016/j.jcma.2013.05.007 \| PMID = 23769878 }}</ref>
	*[[~~Renal~~ cell carcinoma]].<ref name=pmid21484781>{{Cite journal \| last1 = Verma \| first1 = J. \| last2 = Jonasch \| first2 = E. \| last3 = Allen \| first3 = P. \| last4 = Tannir \| first4 = N. \| last5 = Mahajan \| first5 = A. \| title = Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. \| journal = Cancer \| volume = 117 \| issue = 21 \| pages = 4958-65 \| month = Nov \| year = 2011 \| doi = 10.1002/cncr.26138 \| PMID = 21484781 }}</ref>		*[[Clear cell renal cell carcinoma]].<ref name=pmid25467013>{{Cite journal \| last1 = Elaidi \| first1 = R. \| last2 = Harbaoui \| first2 = A. \| last3 = Beuselinck \| first3 = B. \| last4 = Eymard \| first4 = JC. \| last5 = Bamias \| first5 = A. \| last6 = De Guillebon \| first6 = E. \| last7 = Porta \| first7 = C. \| last8 = Vano \| first8 = Y. \| last9 = Linassier \| first9 = C. \| title = Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. \| journal = Ann Oncol \| volume = 26 \| issue = 2 \| pages = 378-85 \| month = Feb \| year = 2015 \| doi = 10.1093/annonc/mdu552 \| PMID = 25467013 }}</ref><ref name=pmid21484781>{{Cite journal \| last1 = Verma \| first1 = J. \| last2 = Jonasch \| first2 = E. \| last3 = Allen \| first3 = P. \| last4 = Tannir \| first4 = N. \| last5 = Mahajan \| first5 = A. \| title = Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. \| journal = Cancer \| volume = 117 \| issue = 21 \| pages = 4958-65 \| month = Nov \| year = 2011 \| doi = 10.1002/cncr.26138 \| PMID = 21484781 }}</ref>

	==See also==		==See also==

Michael: /* Use */

2015-06-05T01:33:02Z

Use

← Older revision		Revision as of 01:33, 5 June 2015
Line 14:		Line 14:
	*[[Lung adenocarcinoma]].		*[[Lung adenocarcinoma]].
	*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal \| last1 = Song \| first1 = Z. \| last2 = Lin \| first2 = B. \| last3 = Shao \| first3 = L. \| last4 = Zhang \| first4 = Y. \| title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. \| journal = J Chin Med Assoc \| volume = 76 \| issue = 9 \| pages = 481-5 \| month = Sep \| year = 2013 \| doi = 10.1016/j.jcma.2013.05.007 \| PMID = 23769878 }}</ref>		*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal \| last1 = Song \| first1 = Z. \| last2 = Lin \| first2 = B. \| last3 = Shao \| first3 = L. \| last4 = Zhang \| first4 = Y. \| title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. \| journal = J Chin Med Assoc \| volume = 76 \| issue = 9 \| pages = 481-5 \| month = Sep \| year = 2013 \| doi = 10.1016/j.jcma.2013.05.007 \| PMID = 23769878 }}</ref>
			*[[Renal cell carcinoma]].<ref name=pmid21484781>{{Cite journal \| last1 = Verma \| first1 = J. \| last2 = Jonasch \| first2 = E. \| last3 = Allen \| first3 = P. \| last4 = Tannir \| first4 = N. \| last5 = Mahajan \| first5 = A. \| title = Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. \| journal = Cancer \| volume = 117 \| issue = 21 \| pages = 4958-65 \| month = Nov \| year = 2011 \| doi = 10.1002/cncr.26138 \| PMID = 21484781 }}</ref>

	==See also==		==See also==

Michael at 15:14, 20 October 2014

2014-10-20T15:14:45Z

← Older revision		Revision as of 15:14, 20 October 2014
Line 23:		Line 23:

	[[Category:Clinical]]		[[Category:Clinical]]
			[[Category:Drugs]]

Michael at 15:06, 20 October 2014

2014-10-20T15:06:51Z

← Older revision		Revision as of 15:06, 20 October 2014
Line 7:		Line 7:

	Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref>		Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref>
	* Sunitinib (Sutent).		* [[Sunitinib]] (Sutent).
	* Sorafenib (Nexavar).		* Sorafenib (Nexavar).
	* Pazopanib (Votrient).		* Pazopanib (Votrient).

Michael at 17:08, 3 October 2014

2014-10-03T17:08:34Z

← Older revision		Revision as of 17:08, 3 October 2014
Line 5:		Line 5:
	* Gefitinib (Iressa).		* Gefitinib (Iressa).
	* Erlotinib (Tarceva).		* Erlotinib (Tarceva).

			Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref>
			* Sunitinib (Sutent).
			* Sorafenib (Nexavar).
			* Pazopanib (Votrient).

	==Use==		==Use==

Michael at 01:26, 9 April 2014

2014-04-09T01:26:15Z

← Older revision		Revision as of 01:26, 9 April 2014
Line 5:		Line 5:
	* Gefitinib (Iressa).		* Gefitinib (Iressa).
	* Erlotinib (Tarceva).		* Erlotinib (Tarceva).

			==Use==
			*[[Lung adenocarcinoma]].
			*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal \| last1 = Song \| first1 = Z. \| last2 = Lin \| first2 = B. \| last3 = Shao \| first3 = L. \| last4 = Zhang \| first4 = Y. \| title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. \| journal = J Chin Med Assoc \| volume = 76 \| issue = 9 \| pages = 481-5 \| month = Sep \| year = 2013 \| doi = 10.1016/j.jcma.2013.05.007 \| PMID = 23769878 }}</ref>

	==See also==		==See also==
	*[[Epidermal growth factor receptor inhibitors]].		*[[Epidermal growth factor receptor inhibitors]].
	*[[Cancer drugs]].		*[[Cancer drugs]].
	*[[Lung adenocarcinoma]].
			==References==
			{{Reflist\|1}}

	[[Category:Clinical]]		[[Category:Clinical]]

Michael: redirect

2012-04-27T18:55:01Z

redirect

← Older revision		Revision as of 18:55, 27 April 2012
Line 9:		Line 9:
	*[[Epidermal growth factor receptor inhibitors]].		*[[Epidermal growth factor receptor inhibitors]].
	*[[Cancer drugs]].		*[[Cancer drugs]].
			*[[Lung adenocarcinoma]].

	[[Category:Clinical]]		[[Category:Clinical]]

Michael: create

2012-03-29T16:13:29Z

create

New page

'''Tyrosine kinase inhibitors''', abbreviated '''TKIs''', are a group of drugs that inhibit the action of tyrosine kinases.

The category includes many cancer drugs - including:
* Imatinib (Gleevec).
* Gefitinib (Iressa).
* Erlotinib (Tarceva).

==See also==
*[[Epidermal growth factor receptor inhibitors]].
*[[Cancer drugs]].

[[Category:Clinical]]